Policy and Politics of Biosimilars under the New Administration

Five months into the new administration, this session will cover the changes in place and potential changes to come for biosimilars. Partner Carlos Angulo and a panel of speakers will explore recently passed and pending legislation, new appointees, threats to the Affordable Care Act, and up-to-date challenges for the biosimilars market including the evolving §101 standard, the impact of Bayh-Dole Act on licensing deals and pricing for biologics and biosimilars going forward, and more.

Visit the conference website to learn more.

Related people
Media contact

Diana L. Courson
Chief Marketing Officer
Email | 202.778.1871